MRSA

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A review of the current literature and future directions.

Many patients with pneumonia are empirically treated with anti-MRSA therapy, leaving antimicrobial stewardship programs faced with the challenge of identifying patients who truly warrant continuation of this therapy.

Antibiotic resistance is highly concerning to researchers, but a team of researchers have identified new synthetic antibiotics with the potential to kill aggressive bacteria.

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality.

The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.

The eNose was also able to recognize methicillin-resistant Staphylococcus aureus (MRSA) from methicillin-sensitive Staphylococcus aureus (MSSA).

Investigators from Massachusetts General Hospital (MGH) have made some interesting findings about methicillin-resistant Staphylococcus aureu (MRSA) that may hold the key to curbing lymphatic repercussions.

SHEA has released expert guidance advising hospitals on when they can safely take patients with multidrug-resistant bacteria off of contact precautions.

Maureen Spencer, Accelerate Diagnostics, sat down with Contagion® to discuss the challenges of disinfecting hospital rooms to prevent C. difficile.

At this year’s annual CHEST meeting, Theravance Biopharma investigators report positive new data pertaining to VIBATIV gleaned from the TOUR study.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.

Proton pumps inhibitors present risks for individuals living with HIV, dalbavancin can treat MRSA-related pneumonia, probiotics prove deadly against C. difficile, patient involvement increases healthcare practitioners’ hand hygiene, and why delafloxacin is a unique antibiotic for skin infections are the topics that make up this week’s Top 5 articles.

Daniel Pilch, PhD, discusses the approach that he and his team took to develop a new drug to fight MRSA.

Researchers from the University of Mississippi report a case of an HIV-positive man with pneumonia due to MRSA who was treated with dalbavancin.

Edmond LaVoie, PhD, describes the properties of prodrug TXA709.

Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.

What's the best recipe for MRSA screening and isolation practices?

The results of a new study show that antibiotic treatment may help improve recovery for minor skin abscesses.

An infection control intervention coming from the VHA resulted in a significant reduction of MRSA in veteran living centers.

Contagion® sat down with Rodrigo Mendes, PhD, to discuss research exploring evolving resistance among antibiotics to treat skin infections.

Prof. Josh Davis, MBBS, PhD, discusses the role of combination therapy when it comes to treating invasive Staphylococcus aureus infections.

Jerod Nagel, PharmD, highlights how rapid diagnostic tools can be utilized in antibiotic stewardship programs to improve outcomes for patients with S. aureus.

Researchers from Montefiore Medical Center presented findings on differential diagnosis of MRSA and Staphylococcus aureus at the 2017 Annual Pediatric Academic Societies (PAS) meeting in San Francisco, California.